Bortezomib for antibody‐mediated rejection of kidney transplant in youth: Associations with donor‐specific antibody

Abstract

AbstractBackgroundAntibody‐mediated rejection is one of the most significant risk factors for allograft dysfunction and failure in children and adolescents with kidney transplants, yet optimal treatment remains unidentified. To date, there are mixed findings regarding the use of Bortezomib, a plasma cell apoptosis inducer, as an adjunct therapy in the treatment of antibody‐mediated rejection.MethodsIn a retrospective single center study, we reviewed the efficacy and tolerability of bortezomib as adjunct therapy for treatment‐refractory antibody‐mediated rejection.ResultsSix patients with a median age of 14.6 years (range 6.9–20.1 years) received bortezomib at a mean of 71 months (range 15–83 months) post‐kidney transplant. Four patients experienced decline in estimated glomerular filtration rate (eGFR) from 4% to 42%. One patient started bortezomib while on hemodialysis and did not recover graft function, and another patient progressed to hemodialysis 6 months after receiving bortezomib. Although DSA did not completely resolve, there was a statistically significant decline in DSA MFI pre and 12‐months post‐BZ (p = .012, paired t‐test) for the subjects who were not on dialysis at the time of bortezomib. Chronic Allograft Damage Index (CADI) score of ≥3 was seen in all six subjects at their biopsy prior to therapy. No adverse effects were reported.ConclusionsBortezomib was well tolerated and resulted in improvements in MFI of DSA among four pediatric subjects without allograft failure, although no effects were observed on eGFR trajectory. Further studies are needed to clarify whether earlier intervention with bortezomib could prevent renal failure progression.